Pular para o conteúdo principal
Ranking Invest

CBAY - CymaBay Therapeutics, Inc.

Segmento: HealthcareCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

Análise Ranking Invest

Valuation estimado
-$ 49.40 Mi
Último Balanço Atualizado: 4T2023

O Ranking Invest utiliza metodologia própria baseada em dados financeiros objetivos, considerando patrimônio, lucratividade e endividamento para estimar o valuation das empresas.

Dados da Empresa

Patrimônio Líquido

$ 292.26 Mi

Dívida Líquida

-$ 92.04 Mi

L4T

-$ 111.68 Mi

MM4T

-18378.72%

Indicadores Básicos

ROE

-38.21%

Índices de Previsibilidade

Receita Líquida

G1.14

Lucro

B0.20

Margem

E1.21

Índices de Tendência

Receita Líquida

C5.53

Lucro

F-7.23

Margem

F-4.74

Índices de Endividamento

DIV/PAT

-0.31

DIV/L4T

0.82

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.